Detail akcie Biocryst Pharm online

Business Summary: BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, BioCryst Pharmaceuticals Inc revenues increased 47% to $468.3M. Net income totaled $18M vs. loss of $62.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest expense decrease of 13% to $64.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.30 to $0.09.